{"organizations": [], "uuid": "68a5b9c929d806f865ed2d26f8f8c43b7db05a3a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180508.html", "section_title": "Archive News &amp; Video for Tuesday, 08 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-xenon-pharmaceuticals-enters-into/brief-xenon-pharmaceuticals-enters-into-at-the-market-equity-offering-sales-agreement-with-stifel-nicolaus-co-idUSFWN1SF1B1", "country": "US", "domain_rank": 408, "title": "BRIEF-Xenon Pharmaceuticals Enters Into At-The-Market Equity Offering Sales Agreement With Stifel, Nicolaus & Co", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.58, "site_type": "news", "published": "2018-05-09T05:50:00.000+03:00", "replies_count": 0, "uuid": "68a5b9c929d806f865ed2d26f8f8c43b7db05a3a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-xenon-pharmaceuticals-enters-into/brief-xenon-pharmaceuticals-enters-into-at-the-market-equity-offering-sales-agreement-with-stifel-nicolaus-co-idUSFWN1SF1B1", "ord_in_thread": 0, "title": "BRIEF-Xenon Pharmaceuticals Enters Into At-The-Market Equity Offering Sales Agreement With Stifel, Nicolaus & Co", "locations": [], "entities": {"persons": [{"name": "stifel", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "nicolaus & co", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "xenon pharmaceuticals inc", "sentiment": "negative"}, {"name": "sec", "sentiment": "none"}, {"name": "stifel", "sentiment": "none"}, {"name": "nicolaus & company", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 8 (Reuters) - Xenon Pharmaceuticals Inc:\n* XENON PHARMACEUTICALS INC - ON MAY 8, CO ENTERED INTO AN ATâ€”MARKET EQUITY OFFERING SALES AGREEMENT WITH STIFEL, NICOLAUS & COMPANY - SEC FILING\n* XENON PHARMACEUTICALS - SALES AGREEMENT TO SELL COMMON SHARES OF CO HAVING SALES PROCEEDS OF UP TO $30 MILLION THROUGH \"AT MARKET\" EQUITY OFFERING PROGRAM Source text: ( bit.ly/2KN4M0A ) Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://bit.ly/2KN4M0A", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-09T05:50:00.000+03:00", "crawled": "2018-05-09T12:40:14.000+03:00", "highlightTitle": ""}